Raymond James & Associates Intra Cellular Therapies, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 158,852 shares of ITCI stock, worth $13.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
158,852
Previous 154,527 2.8%
Holding current value
$13.8 Million
Previous $10.6 Million 9.75%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$67.99 - $80.84 $294,056 - $349,633
4,325 Added 2.8%
158,852 $11.6 Million
Q2 2024

Jul 19, 2024
SELL
$64.76 - $79.84 $98,370 - $121,276
-1,519 Reduced 0.97%
154,527 $10.6 Million
Q1 2024

Apr 22, 2024
BUY
$64.37 - $75.65 $1.11 Million - $1.3 Million
17,191 Added 12.38%
156,046 $10.8 Million
Q4 2023

Jan 16, 2024
SELL
$46.37 - $73.65 $491,058 - $779,953
-10,590 Reduced 7.09%
138,855 $9.94 Million
Q3 2023

Oct 24, 2023
BUY
$52.09 - $64.1 $297,746 - $366,395
5,716 Added 3.98%
149,445 $7.78 Million
Q2 2023

Jul 25, 2023
BUY
$54.67 - $66.44 $34,606 - $42,056
633 Added 0.44%
143,729 $9.1 Million
Q1 2023

Apr 14, 2023
SELL
$43.8 - $56.99 $78,927 - $102,695
-1,802 Reduced 1.24%
143,096 $7.75 Million
Q4 2022

Feb 08, 2023
SELL
$44.07 - $54.45 $847,642 - $1.05 Million
-19,234 Reduced 11.72%
144,898 $7.67 Million
Q3 2022

Oct 25, 2022
BUY
$42.7 - $59.99 $620,516 - $871,774
14,532 Added 9.71%
164,132 $7.64 Million
Q2 2022

Aug 12, 2022
BUY
$43.0 - $65.64 $26,832 - $40,959
624 Added 0.42%
149,600 $8.54 Million
Q1 2022

May 11, 2022
BUY
$38.74 - $62.09 $357,686 - $573,276
9,233 Added 6.61%
148,976 $9.12 Million
Q4 2021

Feb 08, 2022
BUY
$35.2 - $53.42 $202,787 - $307,752
5,761 Added 4.3%
139,743 $7.31 Million
Q3 2021

Nov 02, 2021
BUY
$28.72 - $42.49 $586,864 - $868,240
20,434 Added 18.0%
133,982 $5 Million
Q2 2021

Aug 11, 2021
BUY
$29.3 - $44.5 $888,346 - $1.35 Million
30,319 Added 36.43%
113,548 $4.64 Million
Q1 2021

May 14, 2021
BUY
$30.8 - $39.51 $27,104 - $34,768
880 Added 1.07%
83,229 $2.82 Million
Q4 2020

Feb 12, 2021
SELL
$23.34 - $32.22 $1.71 Million - $2.36 Million
-73,165 Reduced 47.05%
82,349 $2.62 Million
Q3 2020

Nov 04, 2020
SELL
$17.61 - $31.86 $168,140 - $304,199
-9,548 Reduced 5.78%
155,514 $3.99 Million
Q2 2020

Jul 28, 2020
BUY
$14.35 - $26.64 $462,199 - $858,047
32,209 Added 24.24%
165,062 $4.24 Million
Q1 2020

Apr 21, 2020
SELL
$12.31 - $33.12 $28,891 - $77,732
-2,347 Reduced 1.74%
132,853 $2.04 Million
Q4 2019

Feb 12, 2020
BUY
$7.26 - $38.49 $324,195 - $1.72 Million
44,655 Added 49.32%
135,200 $4.64 Million
Q3 2019

Nov 07, 2019
BUY
$7.47 - $14.03 $45,529 - $85,512
6,095 Added 7.22%
90,545 $676,000
Q2 2019

Aug 06, 2019
BUY
$10.65 - $14.29 $168,270 - $225,782
15,800 Added 23.02%
84,450 $1.1 Million
Q1 2019

May 06, 2019
BUY
$10.9 - $14.09 $386,688 - $499,856
35,476 Added 106.94%
68,650 $836,000
Q4 2018

Feb 11, 2019
SELL
$10.36 - $20.96 $389,805 - $788,640
-37,626 Reduced 53.14%
33,174 $378,000
Q3 2018

Nov 14, 2018
BUY
$17.77 - $22.9 $118,170 - $152,285
6,650 Added 10.37%
70,800 $1.54 Million
Q2 2018

Aug 14, 2018
BUY
$17.33 - $23.4 $275,858 - $372,481
15,918 Added 33.0%
64,150 $1.13 Million
Q1 2018

May 14, 2018
BUY
$15.16 - $25.49 $483,331 - $812,672
31,882 Added 195.0%
48,232 $1.02 Million
Q4 2017

Feb 14, 2018
BUY
$14.27 - $16.79 $233,314 - $274,516
16,350
16,350 $237,000

Others Institutions Holding ITCI

# of Institutions
378
Shares Held
84.7M
Call Options Held
319K
Put Options Held
143K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.17B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email